This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wyse, D. G. Search for Related Content PubMed PubMed Citation Articles by Wyse, D. G.

Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis

D. George Wyse, MD, PhD, FACC^*, Mario Talajic, MD, FACC, Gail E. Hafley, MS, Alfred E. Buxton, MD, FACC, L. Brent Mitchell, MD^||, Teresa K. Kus, MD, PhD, FACC^||, Douglas L. Packer, MD, FACC^¶, William H. Kou, MD, FACC^#, Robert Lemery, MD, FACC^**, Peter Santucci, MD, Denise Grimes, RN, Kathleen Hickey, RN, Carolyn Stevens, RN^¶, Steven N. Singh, MD, FACC^|| for the MUSTT Investigators

^* University of Calgary, Calgary, Alberta, Canada
Montreal Heart Institute, Montreal, Quebec, Canada
Duke Clinical Research Institute, Durham, North Carolina, USA
Temple University Hospital School of Medicine, Philadelphia, Pennsylvania, USA
^|| Sacre Coeur Hospital, Montreal, Quebec, Canada
^¶ Mayo Clinic Foundation, Rochester, Minnesota, USA
^# Veteran’s Administration Medical Center, Ann Arbor, Michigan, USA
^** Rhode Island Hospital, Providence, Rhode Island, USA
Rush-Presbyterian Hospital, Chicago, Illinois, USA
Thoracic and Cardiovascular Institute, Lansing, Michigan, USA
Columbia University Medical Center, New York, New York, USA
^|| Veteran’s Administration Medical Center, Washington, District of Columbia, USA

View larger version (16K): [in a new window]   Figure 1 Survival with effective antiarrhythmic drug therapy ([ADT] heavy line) versus no antiarrhythmic therapy ([AT] light line), overall (A) and among patients with noninducible versus stable, inducible ventricular tachycardia (VT) (B).

View larger version (17K): [in a new window]   Figure 2 Arrhythmia-free survival with effective antiarrhythmic drug therapy ([ADT] heavy line) versus no antiarrhythmic therapy ([AT] light line), overall (A) and among patients with noninducible versus stable inducible ventricular tachycardia (VT) (B).

View larger version (14K): [in a new window]   Figure 3 Survival in patients receiving effective antiarrhythmic drug therapy found at drug trial 1 (solid line) versus trial 2 or later drug trials (broken line).

View larger version (26K): [in a new window]   Figure 4 Survival with effective antiarrhythmic drug therapy (heavy line) versus no antiarrhythmic therapy ([AT] light line) by agent used: class 1A and other antiarrhythmic agents (A), sotalol (B), propafenone (C) and amiodarone (D).